Syschem (India) share price & results
- Sept 2026
- Sept 2026
Chandigarh/Haryana-based manufacturer of bulk drugs and pharmaceutical intermediates (APIs), mainly antibiotics, plus contract manufacturing for domestic and export customers.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 113 | +9.4% YoY | Quarterly, as filed | Quarter to Sept 2026 | Revenue from operations as filed. |
| Operating margin | 3.9 | +0.7 pts YoY | Operating profit / revenue | Quarter to Sept 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.9 | +0.5% YoY | Quarterly, as filed | Quarter to Sept 2026 | Profit after tax as filed. |
| Return on equity | 4.39 | +10.3 pts | Trailing twelve months | TTM to Sept 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -1.79 | +7.8 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 42.44 | +6.1 pts | Trailing twelve months | TTM to Sept 2026 | Revenue change against the same period one year earlier. |
Price
Performance −34.8% 1Y
1Y: ₹54.99 on 24 Oct 2025 → ₹35.86. High ₹59.66 (4 Nov 2025), low ₹29.4 (16 Sept 2026).
- Previous close
- ₹33.1
- Market cap
- ₹236 Cr
- 52-week range
- ₹29.4 – ₹59.66
- One year
- −34.44%
- Price to earnings (TTM to Sept 2026)
- 38.37×
- Return on equity (TTM to Sept 2026)
- 4.39%
Overview
- Symbol
- NSE:SYSCHEM
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Syschem (India) Ltd. does
Based on the company's own presentations, annual report and earnings calls.
Syschem (India) Limited manufactures Active Pharmaceutical Ingredients (APIs)/bulk drugs and intermediates, and also undertakes contract manufacturing for third parties. Its product range is concentrated in antibiotic APIs such as Amoxicillin, Ampicillin, Flucloxacillin Sodium, Cloxacillin Sodium, Cephalexin and Cephadroxil. Manufacturing is carried out at its facility in Village Bargodam, Tehsil Kalka, Panchkula (Haryana), which the company has been expanding through backward integration to add dedicated production lines. Products are supplied to consumers and traders both within India and in international markets.
Segments
- Bulk Drugs / API manufacturing
- Contract manufacturing
- Installed capacity
- ~4,200 TPA
- Manufacturing facility
- 1 plant (Village Bargodam, Tehsil Kalka, Panchkula, Haryana); new dedicated lines for Amoxicillin, Cloxacillin, Flucloxacillin and Dicloxacillin sodium under development via backward integration
- Annual production volume (FY25-26)
- 3,039 MT (vs 1,280 MT in FY24-25)
- API product SKUs
- 7+
- Customers and traders served globally
- 200+
- Export footprint
- 12+ countries across 3 continents (top destinations incl. Afghanistan, Bangladesh, China, Nepal, Thailand, Cambodia, Uganda, Kenya, Congo, Sri Lanka, Nigeria, Rwanda)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +1% (quarter to sept 2026 against sept 2025).
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 78 | 119 | 109 | 104 | 142 | 219 | 109 | 113 |
| Expenses | 77 | 117 | 107 | 100 | 136 | 210 | 109 | 109 |
| Operating profit | 1 | 2 | 2 | 3 | 6 | 9 | 1 | 4 |
| Operating margin | 1.5% | 1.6% | 2.3% | 3.2% | 4.2% | 4.3% | 0.5% | 3.9% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | 1 | 1 | 2 | 3 | 5 | 6 | -1 | 2 |
| Tax rate | 0.0% | 54.5% | 0.0% | 25.6% | 15.9% | 68.9% | 15.1% | 10.3% |
| Net profit | 1 | 0 | 2 | 2 | 4 | 2 | -2 | 2 |
| EPS (₹ per share) | 0.13 | 0.11 | 0.38 | 0.44 | 0.96 | 0.36 | -0.34 | 0.36 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 114 | 199 | 332 | 574 |
| Expenses | 105 | 192 | 328 | 553 |
| Operating profit | 9 | 7 | 4 | 21 |
| Other income | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 2 |
| Depreciation | 3 | 3 | 3 | 4 |
| Profit before tax | 6 | 4 | 1 | 15 |
| Net profit | 5 | 3 | 0 | 9 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 | Sept 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 32 | 40 | 44 | 44 | 49 | 54 |
| Reserves | -10 | 17 | 48 | 51 | 73 | 86 |
| Borrowings | 2 | 0 | 0 | 0 | 0 | 1 |
| Other liabilities | 69 | 107 | 126 | 87 | 169 | 125 |
| Total liabilities | 93 | 164 | 217 | 182 | 292 | 265 |
| Fixed assets | 31 | 31 | 53 | 52 | 68 | 65 |
| Capital work in progress | 0 | 4 | 0 | 11 | 0 | 12 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 62 | 129 | 164 | 119 | 224 | 188 |
| Total assets | 93 | 164 | 217 | 182 | 292 | 265 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 4 | 1 | -8 | -26 | -10 | 8 |
| Cash from investing | -4 | -1 | -2 | -6 | -22 | -20 |
| Cash from financing | 0 | 0 | 11 | 32 | 34 | 18 |
| Net cash flow | 0 | 0 | 1 | 0 | 2 | 6 |
| Free cash flow | -1 | -2 | -10 | -32 | -32 | -11 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 31 | 21 | 135 | 126 | 99 | 92 |
| Inventory days | 199 | 152 | 61 | 107 | 81 | 41 |
| Days payable | 221 | 186 | 158 | 198 | 143 | 112 |
| Cash conversion cycle | 9 | -14 | 38 | 34 | 36 | 21 |
| Working capital days | -1 | -15 | 48 | 54 | 39 | 29 |
| Return on capital employed | −29.0% | −12.0% | 38.0% | 11.0% | 1.0% | 16.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 63.38% as of Sept 2026; institutions cut 0.09 pts since Jul 2026.
- Promoters 63.38%
- Domestic institutions 0.06%
- Public 36.55%
Who bought this quarter
since Jul 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 7.33% held
- newly disclosed 5.60% held
- newly disclosed 4.62% held
- newly disclosed 1.09% held
- newly disclosed 0.47% held
- newly disclosed 0.47% held
- +0.17 pp 4.24% held
The same filing shows 0 holders trimming and 6 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Syschem (India) Ltd. above SEBI's 1% disclosure line, and what changed since Jul 2026.
| Holder | Stake | Change |
|---|---|---|
| 11.98% | unchanged | |
| 7.88% | unchanged | |
| 7.88% | unchanged | |
| 7.63% | unchanged | |
| 7.33% | newly disclosed | |
| 7.29% | unchanged | |
| 5.60% | newly disclosed | |
| 4.62% | newly disclosed | |
| 4.24% | +0.17 pp | |
| 1.24% | unchanged | |
| 1.19% | unchanged | |
| 1.16% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Syschem (India) Ltd.
Free account: one company. Everything above stays public.
Write why you follow Syschem (India) Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Syschem (India) Ltd.
Guides on how to read this kind of business and the numbers that matter.